Compare · ARPO vs GWPH
ARPO vs GWPH
Side-by-side comparison of Aerpio Pharmaceuticals, Inc. (ARPO) and GW Pharmaceuticals Plc (GWPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARPO and GWPH operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- ARPO carries a market cap of $425.1M.
- ARPO has more recent analyst coverage (1 ratings vs 0 for GWPH).
- Company
- Aerpio Pharmaceuticals, Inc.
- GW Pharmaceuticals Plc
- Price
- $2.19-1.57%
- $219.01-0.21%
- Market cap
- $425.1M
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2013
- News (4w)
- 0
- 0
- Recent ratings
- 1
- 0
Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.
Latest ARPO
- SEC Form EFFECT filed by Aerpio Pharmaceuticals, Inc.
- SEC Form S-8 filed by Aerpio Pharmaceuticals, Inc.
- SEC Form S-3 filed by Aerpio Pharmaceuticals, Inc.
- Aerpio Pharmaceuticals, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)
- SEC Form 4 filed by Delaney Brendan
- SEC Form 3 filed by new insider Delaney Brendan
- Aerpio Pharmaceuticals, Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Aerpio Pharmaceuticals, Inc. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Leadership Update, Financial Statements and Exhibits
- SEC Form 4 filed by Desai Neil
- SEC Form 4 filed by Reeve Emma
Latest GWPH
- IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel
- Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court
- Study Suggests Whole-Plant Medicinal Cannabis Could Be More Effective Than CBD In Epilepsy Treatment
- SEC Form 15-12B filed by GW Pharmaceuticals Plc
- SEC Form 4: Tovey Christopher J. returned 2,496 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: Cline Darren S returned 5,556 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4 filed by GRYSKA DAVID W
- SEC Form 4: Giacobello Scott M. returned 165,108 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: Secor Alicia returned 10,584 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: Knappertz Volker returned 92,412 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units